Skip to main content
Log in

Adding omalizumab to guideline recommended care may be cost effective in patients with severe allergic asthma,

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Dewilde S, Dale P, Turk F.Cost effectiveness of omalizumab in Swedish asthma patients. European Respiratory Journal Supplement 28 (Suppl. 50): 441s abstr. P2569, Sep 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adding omalizumab to guideline recommended care may be cost effective in patients with severe allergic asthma,. Pharmacoecon. Outcomes News 514, 9 (2006). https://doi.org/10.2165/00151234-200605140-00022

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605140-00022

Keywords

Navigation